ClinicalTrials.gg
CompletedNCT03696550Updated Dec 3, 2021

A Safety and PK Study of IV Eravacycline

A Phase 1 interventional study of Eravacycline (TP-434) in Bacterial Infections, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
131st of 151
19 · median 62
Started
2018
with 7 others
Phase 1
66 of 181
2 open now
Registered
128th of 181
by date
Lead sponsor
4 of 181
Tetraphase Pharmaceuticals, Inc.

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 131st largest by enrollment of the 151 interventional ones that give a count, is one of 8 that started in 2018, is one of 66 in phase 1, and was the 128th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, multi-center study to determine the pharmacokinetics and safety of intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection. Male and Female subjects from 8 to \<18 years of age who fulfill the inclusion/exclusion criteria will be enrolled in this study.

Read the detailed description

This is a Phase 1, open-label, single dose study to evaluate PK, safety, and tolerability of IV eravacycline in children with suspected or confirmed bacterial infection who are receiving systemic antibiotic therapy, other than eravacycline. The study design will allow for evaluation of PK and safety of IV eravacycline in a pediatric population at exposures predicted to be comparable to those already studied in adults. The study design is depicted in Figure 1.

Two cohorts defined by age group will be enrolled simultaneously:

  • Cohort 1: 12 to \<18 years of age (adolescents)
  • Cohort 2: 8 to \<12 years of age (younger children) Eravacycline will be administered as a single IV dose using the optimum dosage determined from PK-PD modeling and model-based simulations of phase 1, 2, and 3 adult data. Blood samples will be collected for PK analysis at predetermined timepoints.
03

Conditions studied

  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female from 8 to \<18 years of age on the day (and assent, if applicable) is obtained
  2. Written informed consent from parent(s) or other legally authorized representative(s) and informed assent from subject (if age appropriate according to local requirements)
  3. Hospitalized, in stable condition, and receiving or plan to receive within 24 hours systemic antibiotic therapy, other than eravacycline, for a suspected or confirmed bacterial infection
  4. Likely to survive the current illness
  5. In the Investigator's opinion, the subject will require hospitalization for at least 24 hours following administration of the study drug
  6. The subject appears to have sufficient intravascular access (peripheral or central) to receive study drug

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of a medical condition that may, in the assessment of the Investigator, impair study participation or pose a significant safety risk or diminish the subject's ability to undergo all study procedures and assessments
  2. Received an product and/or device within 30 days prior to study drug administration or is currently enrolled in any other clinical study involving an investigational product or any other type of medical treatment judged by the Investigator, in consultation with the Medical Monitor, not to be scientifically or medically compatible with this study
  3. History of to tetracycline antibiotics
  4. Prior dosing in this protocol
  5. Unlikely to survive at least 48 hours following administration of study drug
  6. Unable or unwilling, in the judgment of the Investigator, to comply with the protocol
  7. Subject is a child of an employee of the Investigator or study center who has direct involvement in the proposed study or other studies under the direction of the same Investigator or study center, or an immediate family member of the employee or the Investigator, defined as a spouse, parent, child, or sibling, whether biological or legally adopted
  8. Breastfeeding females
  9. Females of [those with menarche and/or thelarche (beginning of breast development)] and sexually active males who are unwilling or unable to use an acceptable method of
  10. Positive pregnancy test in females of childbearing potential
  11. Any other circumstance that, in the opinion of the Investigator, would preclude subject participation in the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age. Age group (years) Dose (mg/kg) 12 to \<18 (Cohort 1) 1.50

    Drug: Eravacycline (TP-434)

  • Experimental
    Cohort 2

    Eravacycline will be administered as a single 60 minute IV infusion according to age. Age group (years) Dose (mg/kg) 8 to \<12 (Cohort 2) 1.75

    Drug: Eravacycline (TP-434)

Interventions

  • Subjects will be stratified by age into 2 cohorts, as follows: * Cohort 1: from 12 to \<18 years of age (N=8) * Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)

    Also known as: Trade name: Xerava™

06

What researchers measure

Primary outcomes

  1. Assess the Pharmacokinetics (PK) parameters for Cmax, maximum observed plasma concentration

    Cmax, maximum observed plasma concentration

    Time frame: Screening (-2 to 1) to Day 7

  2. Assess the Pharmacokinetics (PK) parameters for AUC0-t, area under the plasma concentration-time curve

    AUC0-t, area under the plasma concentration

    Time frame: Screening (-2 to 1) to Day 7

  3. Assess the Pharmacokinetics (PK) parameters for AUC0-inf, area under the plasma concentration-time curve extrapolated to infinite time

    AUC0-inf, area under the plasma concentration-time curve extrapolated to infinite time

    Time frame: Screening (-2 to 1) to Day 7

  4. Assess the Pharmacokinetics (PK) parameters for AUC0-24, area under the plasma concentration-time curve from time 0 to 24 hours after dose

    AUC0-24, area under the plasma concentration-time curve from time 0 to 24 hours after dose

    Time frame: Screening (-2 to 1) to Day 7

  5. Assess the Pharmacokinetics (PK) parameters for t1/2, elimination half-life

    t1/2, elimination half-life

    Time frame: Screening (-2 to 1) to Day 7

  6. Assess the Pharmacokinetics (PK) parameters for Clast,, last observed plasma concentration

    Clast, last observed plasma concentration

    Time frame: Screening (-2 to 1) to Day 7

  7. Assess the Pharmacokinetics (PK) parameters for CL, systemic clearance

    CL, systemic clearance

    Time frame: Screening (-2 to 1) to Day 7

  8. Assess the Pharmacokinetics (PK) parameters for Vd, volume of distribution

    Vd, volume of distribution

    Time frame: Screening (-2 to 1) to Day 7

Secondary outcomes

  1. Adverse Events

    Assess Adverse Events to assess safety and tolerability

    Time frame: From the time of signing the informed consent form to Day 7

  2. A Directed Physical examination including chest/respiratory

    Changes in Physical examination findings including chest/respiratory

    Time frame: Screening (-2 to 1) to Day 7.

  3. A Directed Physical examination including heart/cardiovascular

    Changes in Physical examination findings including heart/cardiovascular

    Time frame: Screening (-2 to 1) to Day 7.

  4. Vital Signs including blood pressure

    Changes in blood pressure

    Time frame: Screening (-2 to 1) to Day 7

  5. Vital Signs including heart rate

    Changes in heart rate

    Time frame: Screening (-2 to 1) to Day 7

  6. Vital Signs including respiratory rate

    Changes in respiratory rate

    Time frame: Screening (-2 to 1) to Day 7

  7. Vital Signs including body temperature

    Changes in body temperature

    Time frame: Screening (-2 to 1) to Day 7

  8. Safety laboratory results including clinical chemistry

    Changes in Clinical laboratory tests including clinical chemistry

    Time frame: Screening (-2 to 1) to Day 7

  9. Safety laboratory tests including hematology

    Changes in Clinical laboratory tests including hematology

    Time frame: Screening (-2 to 1) to Day 7

07

Study locations

7 sites
  • Ronald Reagan University of California Los Angeles Medical Center
    Los Angeles, California 90095, United States
  • Lurie Children's Hospital
    Chicago, Illinois 60611, United States
  • Louisiana State University Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital
    Cleveland, Ohio 44106, United States
  • West Virginia University Hospital
    Morgantown, West Virginia 26506, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Mar 2021, 26 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 26 months is above that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2018
First posted
Oct 4, 2018
StartActual
Dec 20, 2018
Primary completionActual
Mar 14, 2021
CompletionActual
Mar 19, 2021
Last update
Dec 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03696550
Lead sponsor
Tetraphase Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 4, 2018
Start date
Dec 20, 2018
Primary completion
Mar 14, 2021
Completion
Mar 19, 2021
Last update
Dec 3, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eravacycline

Start the discussion